Credible Protein Targets and Curative Strategies for COVID-19 : a Review
© Springer Nature Switzerland AG 2020..
The pandemic of coronavirus infection 2019 (COVID-19) due to the serious respiratory condition created by the coronavirus 2 (SARS-CoV-2) presents a challenge to recognize effective strategies for management and treatment. In general, COVID-19 is an acute disease that can also be fatal, with an ongoing 10.2% case morbidity rate. Extreme illness may bring about death because of enormous alveolar damage and hemorrhage along with progressive respiratory failure. The rapidly expanding information with respect to SARS-CoV-2 research suggests a substantial number of potential drug targets. The most encouraging treatment to date is suggested to be with the help of remdesivir, hydroxychloroquine, and many such repurposed drugs. Remdesivir has a strong in vitro activity for SARS-CoV-2, yet it is not the drug of choice as affirmed by the US Food and Drug Administration and presently is being tried in progressing randomized preliminaries. The COVID-19 pandemic has been the worst worldwide general health emergency of this age and, possibly, since the pandemic influenza outbreak of 1918. The speed and volume of clinical preliminaries propelled to examine potential treatments for COVID-19 feature both the need and capacity to create abundant evidence even in the center of a pandemic. No treatments have been demonstrated as accurate and dependable to date. This review presents a concise precise of the targets and broad treatment strategies for the benefit of researchers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
SN comprehensive clinical medicine - 2(2020), 11 vom: 29., Seite 2067-2076 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Singh, Priya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antisense therapy |
|---|
| Anmerkungen: |
Date Revised 28.03.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s42399-020-00526-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315858303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315858303 | ||
| 003 | DE-627 | ||
| 005 | 20231225155824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s42399-020-00526-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315858303 | ||
| 035 | |a (NLM)33015546 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Singh, Priya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Credible Protein Targets and Curative Strategies for COVID-19 |b a Review |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © Springer Nature Switzerland AG 2020. | ||
| 520 | |a The pandemic of coronavirus infection 2019 (COVID-19) due to the serious respiratory condition created by the coronavirus 2 (SARS-CoV-2) presents a challenge to recognize effective strategies for management and treatment. In general, COVID-19 is an acute disease that can also be fatal, with an ongoing 10.2% case morbidity rate. Extreme illness may bring about death because of enormous alveolar damage and hemorrhage along with progressive respiratory failure. The rapidly expanding information with respect to SARS-CoV-2 research suggests a substantial number of potential drug targets. The most encouraging treatment to date is suggested to be with the help of remdesivir, hydroxychloroquine, and many such repurposed drugs. Remdesivir has a strong in vitro activity for SARS-CoV-2, yet it is not the drug of choice as affirmed by the US Food and Drug Administration and presently is being tried in progressing randomized preliminaries. The COVID-19 pandemic has been the worst worldwide general health emergency of this age and, possibly, since the pandemic influenza outbreak of 1918. The speed and volume of clinical preliminaries propelled to examine potential treatments for COVID-19 feature both the need and capacity to create abundant evidence even in the center of a pandemic. No treatments have been demonstrated as accurate and dependable to date. This review presents a concise precise of the targets and broad treatment strategies for the benefit of researchers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antisense therapy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Protein targets | |
| 650 | 4 | |a Repurposed drugs | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Mishra, Nidhi |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Neelu |e verfasserin |4 aut | |
| 700 | 1 | |a Nisha, Raquibun |e verfasserin |4 aut | |
| 700 | 1 | |a Pal, Ravi Raj |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Samipta |e verfasserin |4 aut | |
| 700 | 1 | |a Maurya, Priyanka |e verfasserin |4 aut | |
| 700 | 1 | |a Saraf, Shubhini A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SN comprehensive clinical medicine |d 2019 |g 2(2020), 11 vom: 29., Seite 2067-2076 |w (DE-627)NLM300071965 |x 2523-8973 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2020 |g number:11 |g day:29 |g pages:2067-2076 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s42399-020-00526-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2020 |e 11 |b 29 |h 2067-2076 | ||